ClinicalTrials.Veeva

Menu

Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes

H

Hadassah Medical Center

Status

Unknown

Conditions

Pregestational Diabetes
Gestational Diabetes
Neurodevelopmental Outcome
IDM (Infant of Diabetic Mothers)
Epigenetic Changes

Study type

Observational

Funder types

Other

Identifiers

NCT01255384
EPI-DIABETES-HMO-CTIL

Details and patient eligibility

About

Pregestational diabetes (PGD) during pregnancy may be associated with an increased rate of spontaneous abortions, intrauterine death and congenital anomalies among the offspring. Although the prevalence of congenital anomalies among the offspring of diabetic mothers is reduced as a result of the improvement of the glycemic control in the early pregnancy, the rate of congenital anomalies is increased and there seems to be an increased rate of neurodevelopmental disorders including some fine and gross motor deficits as well as increased rate of inattention and/or hyperactivity. In gestational diabetes, that develops in the second half of pregnancy (past the period of major organogenesis), there seems to be no increase in the rate of major congenital anomalies but there are some developmental disorders in the offspring.

The exposure of the developing embryo and fetus to diabetic environment (i.e. hyperglycemia, hyperketonemia ext), is known to cause increased oxidative stress and significant changes in gene expression as observed in several experimental diabetic models. We hypothesize that diabetic environment may also cause long lasting epigenetic changes. It is therefore our purpose to evaluate these possible epigenetic changes and correlate their presence with the degree and time of onset of diabetes, (i.e. whether from the beginning as in PGD or in the second half of pregnancy as in GD), the degree of oxidative stress and with the neurodevelopmental outcome of the offspring. Diabetic pregnancies will be compared to a similar number of normal pregnancies in all parameters studied.

Enrollment

300 estimated patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Infants born to women suffering from pre-gestational or gestational diabetes.

Exclusion criteria

  • Non Jewish population
  • Triplets and up
  • Premature infants under 32 weeks
  • Infants suffering from major congenital anomalies
  • Infants with chromosomal aberrations

Trial design

300 participants in 2 patient groups

Non Diabetic-Controls
Description:
Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
Diabetic Pregnancy
Description:
Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years

Trial contacts and locations

1

Loading...

Central trial contact

Zivanit Ergaz Shaltiel, MD; Asher Ornoy, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems